CA2293664A1 - Peptides liberateurs de f.s.h. - Google Patents

Peptides liberateurs de f.s.h. Download PDF

Info

Publication number
CA2293664A1
CA2293664A1 CA002293664A CA2293664A CA2293664A1 CA 2293664 A1 CA2293664 A1 CA 2293664A1 CA 002293664 A CA002293664 A CA 002293664A CA 2293664 A CA2293664 A CA 2293664A CA 2293664 A1 CA2293664 A1 CA 2293664A1
Authority
CA
Canada
Prior art keywords
peptide
seq
recited
xaa
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002293664A
Other languages
English (en)
Inventor
Samuel M. Mccann
Wen H. Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2293664A1 publication Critical patent/CA2293664A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

La LH-RH-III de la lamproie est un puissant facteur libérateur de F.S.H., et il peut être utilisé pour stimuler la fécondité. Des antagonistes de la LH-RH-III de la lamproie peuvent être utilisés pour inhiber la fécondité.
CA002293664A 1997-06-04 1998-06-03 Peptides liberateurs de f.s.h. Abandoned CA2293664A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86915397A 1997-06-04 1997-06-04
US08/869,153 1997-06-04
PCT/US1998/011512 WO1998055136A1 (fr) 1997-06-04 1998-06-03 Peptides liberateurs de f.s.h.

Publications (1)

Publication Number Publication Date
CA2293664A1 true CA2293664A1 (fr) 1998-12-10

Family

ID=25353027

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002293664A Abandoned CA2293664A1 (fr) 1997-06-04 1998-06-03 Peptides liberateurs de f.s.h.

Country Status (4)

Country Link
EP (1) EP0996457A4 (fr)
JP (1) JP2000513749A (fr)
CA (1) CA2293664A1 (fr)
WO (1) WO1998055136A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
HU221407B1 (hu) 1997-03-28 2002-09-28 Gyula Magvasi Ektodermális eredetû szövetekben fellépõ tumoros burjánzást gátló hatóanyag és készítmény, valamint eljárás elõállításukra
DE10050831A1 (de) * 2000-10-05 2002-05-02 Veyx Pharma Gmbh Verfahren zum Zyklusstart bei weiblichen Zuchttieren
CN101264096B (zh) * 2007-03-12 2011-11-09 中国医学科学院药物研究所 人参皂苷Rg1在制备生精产品中的应用
JP5764854B2 (ja) * 2009-11-05 2015-08-19 株式会社サウスプロダクト ポリクローナル抗体およびその利用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
DE69532578T2 (de) * 1994-08-10 2004-12-23 Lovas, Sandor, Omaha NEUARTIGE GnRH - ANALOGE MIT ANTITUMORALEN EFFEKTEN UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN

Also Published As

Publication number Publication date
JP2000513749A (ja) 2000-10-17
EP0996457A1 (fr) 2000-05-03
EP0996457A4 (fr) 2001-09-19
WO1998055136A1 (fr) 1998-12-10

Similar Documents

Publication Publication Date Title
US5084555A (en) An octapeptide bombesin analog
EP1272206B1 (fr) Un analogue du GnRH de poulet II pour la reduction de la croissance de cellules tumorales
JP4346115B2 (ja) Ｌｈ−ｒｈペプチド類似体、その使用及びそれを含有する薬用組成物
US8258100B2 (en) Ligand/lytic peptide methods of use
US6307017B1 (en) Octapeptide bombesin analogs
Kerdelhue et al. Binding studies of substance P anterior pituitary binding sites: changes in substance P binding sites during the rat estrous cycle
CA2097192C (fr) Antagonistes de la bombesine
EP0592512A1 (fr) Analogues non desensibilisants de gonadoliberine et d'autres ligands biologiquement actifs
Haviv et al. Active reduced-size hexapeptide analogs of luteinizing hormone-releasing hormone
CA2293664A1 (fr) Peptides liberateurs de f.s.h.
CZ84893A3 (en) Method of projecting and synthesizing lhrh antagonists
US6300471B1 (en) FSH-releasing peptides
Labrie et al. Inhibition of luteinizing hormone release by analogs of luteinizing hormone-releasing hormone (LHRH) in vitro
EP0988048A1 (fr) Compositions de peptides lytiques/ligands et leurs procedes d'utilisation
US6407205B1 (en) FSH-releasing peptides
Nekola et al. LHRH antagonists in females
US5382568A (en) Decapeptide having dopamine stimulating activity
US5593965A (en) Anti-tumor effects of GnRH-III
Coy et al. Suppression of gonadotropin release and ovulation in animals by inhibitory analogs of luteinizing hormone-releasing hormone
Schally et al. Hypothalamic hormones regulating pituitary (and other) functions: their physiology and biochemistry as well as recent studies with their synthetic analogues
SCHALLY Aspects of hypothalamic regulation of the pituitary gland with major emphasis on its implications for the control of reproductive processes
Chihara et al. AV Schally*, DH Coy*, A. Arimura*, TW Redding*, AJ Kastin*, C. Meyers*, J. Seprodi*, R. Chang*, W.-Y. Huang
SCHALLY et al. HORMONES (RI-I), ESPECIALLY LH-RH
Sherwood et al. Primary Structure and Function of Three Gonadotropin
NEKOLA et al. RECENT ADVANCES IN THE DEVELOPMENT OF LHRH ANTAGONISTS

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20050603